 CAMBRIDGE, Mass., Dec. 11, 2020 GLOBE NEWSWIRE -- Solid Biosciences Inc. Nasdaq: SLDB, a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy Duchenne, today announced that it has entered into a securities purchase agreement with a select group of institutional investors and accredited investors for a 90 million private placement, which is expected to close on or about December 15, 2020, subject to the satisfaction of customary closing conditions. 